NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Packaged Foods · USD

Niagen Bioscience, Inc. (NAGE) Stock Analysis

Niagen Bioscience, Inc. (NAGE) is a Packaged Foods stock listed on NASDAQ and quoted in US Dollar.

NAGE

$3.17

+$0.06 (+1.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NAGE with… →

NAGE Key Statistics

As of Sep 4, 2026
Trading
Open
$3.10
Previous Close
$3.11
Day's Range
3.07–3.17
52-Week Range
2.87–10.52
Volume
256.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.09
Valuation
Market Cap
$250.83M
P/E Ratio
16.68
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
31.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.94
EPS (ttm)Profit attributable to each share over the last twelve months.
0.19
Financials (FY)
Revenue (FY)
$129.42M+29.95%
Net Income (FY)
$17.38M+103.30%
Profit marginThe share of revenue left as profit after all costs and taxes.
12.39%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
79.13M
1-Year Return
−65.99%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
656.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NAGE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−50.16%
2025+19.77%
2024+271.33%
2023−14.88%
2022−55.08%
2021−22.08%
2020+11.37%
2019+25.66%
2018−41.67%
2017+77.64%
2016 (partial year)−18.87%

As of September 4, 2026.

NAGE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$129.42M$17.38M13.4%
2024$99.60M$8.55M8.6%
2023$83.57M−$4.94M−5.9%
2022$72.05M−$16.54M−23.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$129.42M$83.19M$14.30M$17.38M13.4%
2024$99.60M$61.59M$7.73M$8.55M8.6%
2023$83.57M$50.78M−$5.60M−$4.94M−5.9%
2022$72.05M$42.80M−$18.63M−$16.54M−23.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NAGE Valuation vs Packaged Foods Median

Median of 76 stocks
MetricNAGEPackaged Foods medianvs median
P/E16.6815.478% above
P/S ratio1.940.65199% above
Profit margin12.39%0.50%11.9 pts above

Medians across 76 Packaged Foods stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Niagen Bioscience, Inc. (NAGE) is capitalised at $250.83M on the latest close. It is classified in the Packaged Foods industry, within the Consumer Defensive sector. The company reports 117 employees.

Over the past 52 weeks the price has ranged from $2.87 to $10.52. The most recent close on file for NAGE is $3.17, dated September 4, 2026. That is +$0.06 (+1.93%) against the previous close. The latest close sits 10.45% above that 52-week low.

Financial Health

In fiscal 2025, Niagen Bioscience, Inc. reported revenue of $129.42M. Against the prior fiscal year total of $99.60M, that is a change of +29.95%. The same year closed with net income of $17.38M. That is +103.30% against the prior fiscal year. Profit margin runs at 12.39%. That is 11.9 percentage points above the Packaged Foods median of 0.5%. Trailing earnings per share are 0.19.

Across the 4 fiscal years on file, revenue moves from $72.05M in 2022 to $129.42M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 16.68. That is 7.82% above the Packaged Foods median of 15.47. The forward P/E on file is 31.7. Measured against sales, the shares trade at 1.94 times revenue. On price-to-sales that is 199.21% above the Packaged Foods median of 0.65. The medians here are taken across 76 Packaged Foods companies that report the metric.

Beta against the wider market is reported at 2.09. Daily returns over the trailing 10 years annualize to a volatility of 78.51%. Over the trailing twelve months the price has returned −65.99%. Across 10 years the annualized return works out at −0.64%.

Growth & Income

No dividend is on file for NAGE.

So far in 2026 the price is −50.16%. Across the complete calendar years on file, 2024 returned +271.33% and 2022 returned −55.08%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Niagen Bioscience, Inc. (NAGE) operates in the Packaged Foods industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Niagen Bioscience, Inc. NAGE $250.83M 16.7
The Kraft Heinz Company KHC $29.47B —
General Mills, Inc. GIS $20.47B —
Saputo Inc. SAP.TO $15.93B 23.1

The Packaged Foods industry average P/E ratio is 15.5x. Niagen Bioscience, Inc. trades at a P/E of 16.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Packaged Foods Stocks

KHC

The Kraft Heinz Company

$29.47B

 GIS

General Mills, Inc.

$20.47B

 SAP.TO

Saputo Inc.

$15.93B

 MKC

McCormick & Company, Incorporated

$14.00B

 JBS

JBS N.V.

$13.95B

 SJM

The J. M. Smucker Company

$13.47B
View all Packaged Foods stocks →

Popular Consumer Defensive Stocks

WMT

Walmart Inc.

$852.63B

 COST

Costco Wholesale Corporation

$406.11B

 KO

The Coca-Cola Company

$378.93B

 PG

The Procter & Gamble Company

$340.13B

 PM

Philip Morris International Inc.

$284.49B
View all Consumer Defensive stocks →

About Niagen Bioscience, Inc.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Visit website →